Compare Stocks: IPHA, FTH, NVCT, and PHAR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTH Sensei Biotherapeutics	$17.08 -15.0%	$30.37	$7.45 ▼ $42.14	$441.35M	-0.29	335,935 shs	353,706 shs
IPHA Innate Pharma	$1.50	$1.83	$1.17 ▼ $2.71	$167.58M	0.72	37,905 shs	11,621 shs
NVCT Nuvectis Pharma	$20.05 -4.0%	$21.82	$5.55 ▼ $29.27	$654.51M	-0.24	173,180 shs	107,947 shs
PHAR Pharming Group	$11.20 +5.0%	$10.67	$9.11 ▼ $21.34	$792.71M	-0.05	17,294 shs	25,784 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTH Sensei Biotherapeutics	0.00%	-9.15%	-41.20%	-39.63%	+1,707,999,900.00%
IPHA Innate Pharma	0.00%	+4.90%	-11.76%	-15.73%	-28.23%
NVCT Nuvectis Pharma	0.00%	+7.80%	-7.30%	+3.83%	+238.68%
PHAR Pharming Group	0.00%	+19.59%	+7.28%	-11.15%	-14.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTH Sensei Biotherapeutics	$17.08 -15.0%	$30.37	$7.45 ▼ $42.14	$441.35M	-0.29	335,935 shs	353,706 shs
IPHA Innate Pharma	$1.50	$1.83	$1.17 ▼ $2.71	$167.58M	0.72	37,905 shs	11,621 shs
NVCT Nuvectis Pharma	$20.05 -4.0%	$21.82	$5.55 ▼ $29.27	$654.51M	-0.24	173,180 shs	107,947 shs
PHAR Pharming Group	$11.20 +5.0%	$10.67	$9.11 ▼ $21.34	$792.71M	-0.05	17,294 shs	25,784 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTH Sensei Biotherapeutics	0.00%	-9.15%	-41.20%	-39.63%	+1,707,999,900.00%
IPHA Innate Pharma	0.00%	+4.90%	-11.76%	-15.73%	-28.23%
NVCT Nuvectis Pharma	0.00%	+7.80%	-7.30%	+3.83%	+238.68%
PHAR Pharming Group	0.00%	+19.59%	+7.28%	-11.15%	-14.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTH Sensei Biotherapeutics	3.00	Buy	$56.25	229.33% Upside
IPHA Innate Pharma	2.67	Moderate Buy	$6.67	344.44% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	80.80% Upside
PHAR Pharming Group	2.20	Hold	$38.67	245.24% Upside

Current Analyst Ratings Breakdown

Latest IPHA, FTH, NVCT, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	FTH Sensei Biotherapeutics	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	FTH Sensei Biotherapeutics	Lifesci Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/24/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$39.00
9/23/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$38.00
9/22/2026	IPHA Innate Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/22/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$37.00
9/21/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/17/2026	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$9.00
9/16/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$70.00
9/15/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
IPHA Innate Pharma	$10.19M	16.45	N/A	N/A	($0.26) per share	-5.77
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
PHAR Pharming Group	$366.48M	2.16	$0.20 per share	55.85	$3.95 per share	2.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
IPHA Innate Pharma	-$55.64M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	93.33	40.00	N/A	2.51%	3.40%	1.90%	10/27/2026 (Estimated)

Latest IPHA, FTH, NVCT, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	NVCT Nuvectis Pharma	-$0.22	N/A	N/A	N/A	N/A	N/A
10/27/2026	Q3 2026 TU	PHAR Pharming Group	$0.15	N/A	N/A	N/A	$117.60 million	N/A
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTH Sensei Biotherapeutics	N/A	19.69	19.69
IPHA Innate Pharma	N/A	0.60	N/A
NVCT Nuvectis Pharma	N/A	1.68	1.68
PHAR Pharming Group	0.34	3.01	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTH Sensei Biotherapeutics	10.50%
IPHA Innate Pharma	0.16%
NVCT Nuvectis Pharma	96.77%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
FTH Sensei Biotherapeutics	7.00%
IPHA Innate Pharma	31.89%
NVCT Nuvectis Pharma	28.55%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTH Sensei Biotherapeutics	29	25.84 million	24.03 million	Not Optionable
IPHA Innate Pharma	163	111.72 million	76.09 million	Not Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Optionable
PHAR Pharming Group	407	70.78 million	69.31 million	Not Optionable

IPHA, FTH, NVCT, and PHAR Headlines

Recent News About These Companies

Pharming Group (PHAR) Expected to Announce Earnings on Tuesday

October 25 at 4:12 AM | americanbankingnews.com

Pharming Group (PHAR) Projected to Post Quarterly Earnings on Tuesday

October 25 at 3:40 AM | marketbeat.com

HC Wainwright Weighs in on Pharming Group FY2027 Earnings

October 25 at 1:29 AM | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Pharming Group (PHAR) and BioNTech SE (BNTX)

October 24 at 7:15 PM | theglobeandmail.com

Analysts Are Bullish on These Healthcare Stocks: Pharming Group (PHAR), Inventiva (IVA)

October 24 at 7:15 PM | theglobeandmail.com

Pharming Group (NASDAQ:PHAR) Upgraded to "Hold" at Wall Street Zen

October 24 at 4:06 AM | marketbeat.com

Pharming Group (NASDAQ:PHAR) Stock Jumps 8% - Still a Buy?

October 23 at 11:59 AM | marketbeat.com

FY2027 EPS Estimate for Pharming Group Lifted by Analyst

October 23 at 8:27 AM | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Should You Buy?

October 22 at 10:59 AM | marketbeat.com

Akebia Therapeutics (NASDAQ:AKBA) vs. Pharming Group (NASDAQ:PHAR) Financial Analysis

October 22 at 3:59 AM | americanbankingnews.com

Pharming Group announces third quarter 2026 revenues above market expectations

October 22, 2026 | globenewswire.com

Pharming Group (NASDAQ:PHAR) Sets New 52-Week Low - Here's Why

October 21, 2026 | americanbankingnews.com

Pharming Group (NASDAQ:PHAR) Hits New 52-Week Low - Time to Sell?

October 19, 2026 | marketbeat.com

Pharming Reports Positive Phase II Data For Leniolisib In Rare Genetic Immune Disorders

October 14, 2026 | rttnews.com

Pharming's Leniolisib Shows Promise Beyond APDS In Rare Genetic Immune Disorders

October 14, 2026 | rttnews.com

Pharming Reports Positive Phase 2 Data for Leniolisib in Genetic Immune Disorders

October 14, 2026 | marketscreener.comM

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

October 14, 2026 | globenewswire.com

Pharming Group (NASDAQ:PHAR) Reaches New 52-Week Low - Should You Sell?

October 13, 2026 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Reaches New 12-Month Low - Here's Why

October 7, 2026 | marketbeat.com

HC Wainwright Raises Earnings Estimates for Pharming Group

October 2, 2026 | marketbeat.com

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Stock Rated "Hold" by Wall Street Analysts

October 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPHA, FTH, NVCT, and PHAR Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

$17.08 -3.02 (-15.02%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$17.08 0.00 (0.00%)

As of 10/23/2026 07:30 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Innate Pharma NASDAQ:IPHA

$1.50 0.00 (0.00%)

Closing price 10/23/2026 03:58 PM Eastern

Extended Trading

$1.49 -0.01 (-0.67%)

As of 10/23/2026 06:48 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Nuvectis Pharma NASDAQ:NVCT

$20.05 -0.84 (-4.02%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$20.00 -0.05 (-0.22%)

As of 10/23/2026 04:04 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Pharming Group NASDAQ:PHAR

$11.20 +0.53 (+4.97%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$11.14 -0.05 (-0.49%)

As of 10/23/2026 07:30 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, FTH, NVCT, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, FTH, NVCT, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, FTH, NVCT, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IPHA, FTH, NVCT, and PHAR Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

Innate Pharma NASDAQ:IPHA

Nuvectis Pharma NASDAQ:NVCT

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, FTH, NVCT, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, FTH, NVCT, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, FTH, NVCT, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IPHA, FTH, NVCT, and PHAR Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

Innate Pharma NASDAQ:IPHA

Nuvectis Pharma NASDAQ:NVCT

Pharming Group NASDAQ:PHAR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools